AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins

被引：10
|
作者：
Evers, Melvin M. [1 ]
Konstantinova, Pavlina [1 ]
机构：
[1] UniQure Biopharma BV, Res, Amsterdam, Netherlands
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2020年 / 20卷 / 10期
关键词：
Huntington disease; huntingtin lowering; HTT; antisense oligonucleotide; ASO; adeno-associated virus; AAV5; microRNA; EMBRYONIC LETHALITY; SUPPRESSION; MODEL; INACTIVATION; IMPROVEMENT; APOPTOSIS; PROTEIN; RNA;
D O I：
10.1080/14712598.2020.1792880
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：1121 / 1124
页数：4
相关论文
共 50 条
  • [31] Lowering the Pathogenic Exon 1 HTT Fragment by AAV5-miRNA Gene Therapy
    Sogorb-Gonzalez, Marina
    Mariet, Fanny
    Konstantinova, Pavlina
    Van Deventer, Sander J.
    Evers, Melvin M.
    Valles, Astrid
    MOLECULAR THERAPY, 2020, 28 (04) : 111 - 111
  • [32] Lowering the Pathogenic Exon 1 HTT Fragment by AAV5-miRNA Gene Therapy
    Sogorb-Gonzalez, Marina
    Mariet, Fanny
    Konstantinova, Pavlina
    van Deventer, Sander J.
    Evers, Melvin M.
    Valles, Astrid
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 21 - 21
  • [33] Development of an AAV5-Based Gene Therapy for Fabry Disease
    Liefhebber, Jolanda M. P.
    van der Zon, Tom
    Paerels, Lieke
    Ferraz, Maria J.
    Ottenhoff, Roelof
    Zancanella, Vanessa
    Au, Betty
    Kuo, Chi-Lin
    de Vries, Carlie J. M.
    Evers, Melvin M.
    Konstantinova, Pavlina
    Aerts, Johannes M. F. G.
    Van Deventer, Sander J.
    Liu, Ying Poi
    MOLECULAR THERAPY, 2019, 27 (04) : 442 - 443
  • [34] Development of an AAV5-based gene therapy for Fabry disease
    Liu, Ying Poi
    Liefhebber, Jolanda M. P.
    van der Zon, Tom
    Paerels, Lieke
    Ferraz, Maria J.
    Ottenhoff, Roelof
    Zancanella, Vanessa
    Au, Betty
    Kuo, Chi-Lin
    de Vries, Carlie J. M.
    Evers, Melvin M.
    Konstantinova, Pavlina
    Aerts, Johannes M. F. G.
    Van Deventer, Sander J.
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S99 - S99
  • [35] Development of an AAV-Based, RNA-Targeting Gene Therapy for the Treatment of Huntington's Disease
    Geddes, Claire E.
    Roth, Daniela
    Ta, Angeline
    Wilson, Alistair
    Gutierrez, Haydee
    Narayan, Nandini
    Angelis, Dimitrios
    Fang, Lydia
    Berlin, Aaron
    Nachtrab, Greg
    Gibbs, Dan
    Zisoulis, Dimitrios
    Batra, Ranjan
    MOLECULAR THERAPY, 2021, 29 (04) : 271 - 271
  • [36] Gene therapy for Huntington's disease
    Ramaswamy, Shilpa
    Kordower, Jeffrey H.
    NEUROBIOLOGY OF DISEASE, 2012, 48 (02) : 243 - 254
  • [37] AAV-Mediated CYP46A1 Gene Therapy as a Strategy to Counteract Huntington's Disease
    Cartier, Nathalie
    Alves, Sandro
    Christaller, Wilhelm
    Subashi, Enedja
    Kacher, Radia
    Lamaziere, Antonin
    Despres, Gaetan
    Piguet, Francoise
    Saudou, Frederic
    Caboche, Jocelyne
    Betuing, Sandrine
    MOLECULAR THERAPY, 2018, 26 (05) : 308 - 309
  • [38] Attitudes Towards Gene Therapy in Huntington Disease
    Bardakjian, Tanya M.
    Gonzalez-Alegre, Pedro
    NEUROTHERAPEUTICS, 2017, 14 (01) : 249 - 249
  • [39] AAV-Based Prion Protein-Lowering Gene Therapy for CJD
    Zhang, Jun
    Camacho, Manuel
    Bei, Fengfeng
    Kong, Qingzhong
    MOLECULAR THERAPY, 2024, 32 (04) : 144 - 144
  • [40] Cell and gene therapy for Huntington's disease
    Song, Jihwan
    TISSUE ENGINEERING PART A, 2022, 28 : 346 - 346
12345